Faculty, Staff and Student Publications
Language
English
Publication Date
1-1-2025
Journal
Frontiers in Pharmacology
DOI
10.3389/fphar.2025.1557112
PMID
40191420
PMCID
PMC11968745
PubMedCentral® Posted Date
3-21-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and the second most common in children. Despite the introduction of targeted therapies, AML survival rates have shown limited improvement, particularly among older patients. This study explored personalized treatment strategies for AML by proposing a novel subtyping method. Through unsupervised clustering based on the enrichment scores of 14 pathways related to metabolism, immunity, DNA repair, and oncogenic signaling, we identified three AML subtypes: DNA repair (DR), immune-enriched (ImE), and immune-deprived (ImD), consistent in four independent datasets. DR is marked by high expression of DNA repair and metabolic pathways, high stemness and proliferation potential, as well as high sensitivity to chemotherapy. ImD is characterized by low expression of immune and oncogenic pathways, favorable survival prognosis, low mutation rates of RUNX1 and TP53, high homeostasis, and low migration potential. ImE exhibits high enrichment of immune and oncogenic pathways, low stemness and proliferation capacity, low homeostasis, high migration potential, and low sensitivity to chemotherapy. Our pathway enrichment-based subtyping approach would offer a promising framework for understanding the molecular heterogeneity of AML and guiding personalized treatment of this disease.
Keywords
AML, acute myeloid leukemia, pathway enrichment analysis, transcriptome (RNA-seq), drug sensitivity, subtype
Published Open-Access
yes
Recommended Citation
Zhong, Ling; Luo, Jiangti; Dong, Junze; et al., "Identifying Acute Myeloid Leukemia Subtypes Based on Pathway Enrichment" (2025). Faculty, Staff and Student Publications. 1010.
https://digitalcommons.library.tmc.edu/uthshis_docs/1010